rs7660895 — SLC2A9

Intronic variant in the major renal urate transporter GLUT9; the G allele reduces renal urate excretion, raising serum uric acid and increasing gout risk, with stronger effects in women than men

See your personal result for SLC2A9

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC2A9 rs7660895 — The Renal Urate Gate

Every day, your kidneys filter almost the entire blood volume of uric acid and then reabsorb roughly 90% of it back into the bloodstream. The protein that does most of this reabsorption — GLUT9, encoded by SLC2A911 GLUT9, encoded by SLC2A9
Solute Carrier Family 2 Member 9, also called the Glucose Transporter 9. Despite the name, urate is its primary physiological substrate in the kidney — is the dominant gatekeeper of serum urate levels. Intronic variants in SLC2A9, including rs7660895, tune how efficiently GLUT9 functions in the kidney's proximal tubule, and the direction of the effect is clinically consequential: more reabsorption means higher serum uric acid; less means lower, more excretion, and a reduced risk of gout.

The Mechanism

GLUT9 exists in two isoforms. The long isoform (GLUT9a) localises to the basolateral membrane of proximal tubule cells, facing the bloodstream, and is primarily responsible for returning urate from tubule cells into circulation. The short isoform (GLUT9b) sits on the apical (urine-facing) membrane and retrieves urate from the tubular lumen. Together, they create an efficient urate recycling loop that keeps most filtered urate from reaching the urine.

rs7660895 is an intronic variant that does not change the GLUT9 protein sequence, but it likely influences gene expression or splicing efficiency — a common mechanism for intronic variants in this tightly regulated gene. The G allele is associated with higher GLUT9 activity or expression, leading to greater renal urate reabsorption and elevated serum uric acid. The A allele is associated with somewhat reduced reabsorption efficiency and lower circulating urate. The effect follows an additive model: each G allele incrementally raises serum uric acid concentration.

The Evidence

Two landmark papers published simultaneously in Nature Genetics in April 2008 established SLC2A9 as the largest-effect common genetic determinant of serum uric acid. Döring et al.22 Döring et al.
Döring A et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet, 2008 studied 1,644 individuals from the German KORA cohort, finding that intronic SLC2A9 minor alleles lower serum uric acid by 0.23–0.36 mg/dL per copy — larger than any other common variant — with the effect approximately twice as large in women (reducing SUA by ~0.45 mg/dL per copy) as in men (~0.25 mg/dL per copy). SLC2A9 genotype explained 6% of SUA variance in women and 1.2% in men.

Vitart et al.33 Vitart et al.
Vitart V et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet, 2008 independently confirmed the association in Croatian island populations, a UK cohort, and Germans, demonstrating that protective SLC2A9 variants explain 1.7–5.3% of SUA variance and directly reduce gout risk. They also confirmed GLUT9's urate transport function in cell-based assays, establishing the biological mechanism.

A subsequent dietary interaction study by Batt et al. (2014)44 Batt et al. (2014)
Batt C et al. Sugar-sweetened beverage consumption: a risk factor for prevalent gout with SLC2A9 genotype-specific effects on serum urate and risk of gout. Ann Rheum Dis, 2014 found that high sugar-sweetened beverage consumption partially abolishes SLC2A9's protective effect: each daily SSB serving increased gout risk by 12–15% regardless of genotype, and among protective-allele carriers the relative benefit was substantially eroded at high intake levels. A parallel study Dalbeth et al. (2013)55 Dalbeth et al. (2013)
Dalbeth N et al. Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load. Ann Rheum Dis, 2014 showed that a single fructose load raised serum urate more in G-allele homozygotes and less in protective-allele carriers, with the latter showing greater compensatory urate excretion.

Practical Actions

The G allele raises serum uric acid through reduced renal excretion efficiency. The two most actionable levers are dietary: limiting fructose (especially from sugar-sweetened beverages and concentrated fruit juice) and moderating purine-rich foods (organ meats, shellfish, red meat) to reduce the urate production load the kidneys must clear. Monitoring serum urate periodically allows early intervention if levels trend toward the gout-risk threshold (6 mg/dL / 357 µmol/L).

The sex-specific effect is clinically important: in women, SLC2A9 variants account for roughly five times more urate variance than in men. Pre-menopausal women with GG genotype face a meaningfully greater absolute increase in uric acid from dietary exposures than men with the same genotype, while also having lower baseline serum urate due to oestrogen's uricosuric effect. Post-menopause, oestrogen loss unmasks the genetic risk and serum urate often rises sharply in GG women.

Interactions

rs7660895 sits within the same SLC2A9 locus as several other well-studied intronic variants (rs6449213, rs7442295, rs6855911, rs11722228) that are in moderate to high linkage disequilibrium. Multiple independent signals exist at this locus; the combined burden of risk alleles across these variants is additive and explains more SUA variance than any single SNP.

The missense variant rs16890979 (p.Val282Ile) is a distinct functional variant in SLC2A9 that reduces GLUT9 transport capacity through a different mechanism (protein function rather than expression/splicing). Individuals carrying the protective allele at both rs7660895 and rs16890979 have substantially lower serum uric acid than those carrying risk alleles at both, consistent with additive effects from independent functional perturbations of the same transporter.

Nutrient Interactions

fructose altered_metabolism
purines increased_need

Genotype Interpretations

What each possible genotype means for this variant.

AA Enhanced Urate Excretion Beneficial

Protective SLC2A9 genotype — efficient renal urate excretion

You carry two copies of the rare A allele at rs7660895. This genotype is associated with the most efficient renal urate excretion across SLC2A9 studies, resulting in the lowest serum uric acid levels of the three genotypes. Only about 10% of people globally share this genotype; it is somewhat more common in African and East Asian populations (~16%) than in Europeans (~6%). Your genetic profile provides a natural buffer against uric acid accumulation, reducing your baseline risk of hyperuricemia and gout from this locus.

AG Intermediate Urate Reabsorption Intermediate

One copy of the G allele — moderately elevated renal urate retention

One G allele nudges your renal urate reabsorption slightly above the AA baseline. Research across German, Croatian, and UK cohorts consistently shows that each G allele incrementally reduces GLUT9 excretion efficiency. The sex-specific differential is important: women with one G allele lose roughly twice the urate excretion benefit per allele compared to men, reflecting oestrogen's independent uricosuric effect and its interaction with GLUT9. Fructose is a particular concern: fructose is converted to urate in the liver (bypassing feedback regulation), and SLC2A9 genotype-specific studies show the acute urate rise from a fructose challenge is larger in G-allele carriers and smaller in those with more A alleles.

GG Reduced Urate Excretion High Risk

Homozygous G allele — reduced renal urate excretion and elevated gout risk

Two G alleles maximally activate the renal urate reabsorption phenotype encoded by SLC2A9. The kidneys filter uric acid freely but GLUT9 retrieves most of it before it reaches the urine; with the GG genotype, this retrieval operates at higher efficiency, returning more urate to circulation and raising serum levels. Large-effect intronic SLC2A9 variants have been associated with reduced gout risk of 25–65% per minor allele carried — conversely, absence of the protective allele (GG homozygosity) represents the background population risk or above.

The interaction with diet is documented and clinically significant. Fructose from sugar-sweetened beverages is metabolised in the liver to urate without feedback inhibition, producing a bolus that the kidney must clear. In SLC2A9 G-allele carriers, the acute serum urate rise from a fructose load is larger and urinary excretion less compensatory than in A-allele carriers. This means that dietary fructose exposure has a disproportionately large impact on serum urate in GG individuals compared with AA.

In women, the risk compounds post-menopause. Pre-menopausal oestrogen acts independently to promote urate excretion, partially masking the GG genotype's effect. After menopause, oestrogen withdrawal unmasks the full SLC2A9 contribution, and GG women often experience a sharp rise in serum urate at this transition — sometimes crossing into hyperuricemic range for the first time.